This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Miltenyi Biotec
product type :
antibody
product name :
CD34 Antibody, anti-human, APC, REAfinity™
catalog :
130-120-519
quantity :
30 tests in 60 µL
price :
136 USD
clonality :
monoclonal
host :
human
conjugate :
APC
clone name :
REA1164
reactivity :
human
application :
immunohistochemistry, immunocytochemistry, flow cytometry
citations: 7
Reference |
---|
Lian W, Zhang H, Wang K, Jiang J, Su Z, Yu Z. Varying levels of 6-keto-prostaglandin F1α and thromboxane B2 in serum and endothelialization and hyperplasia in small-diameter grafts seeded with CD34+ bone marrow cells in canines. Exp Ther Med. 2014;7:1123-1129 pubmed
|
Stull R, Hyun W, Pallavicini M. Simultaneous flow cytometric analyses of enhanced green and yellow fluorescent proteins and cell surface antigens in doubly transduced immature hematopoietic cell populations. Cytometry. 2000;40:126-34 pubmed
|
product information
MB Cataloge Number :
130-120-519
Catalog Number :
130-120-519
Product Name :
CD34 Antibody, anti-human, APC, REAfinity™
Product Type :
Primary antibodies, Recombinant antibodies
Host Species :
recombinant human IgG1
Clonality :
monoclonal
Conjugation :
APC
Antigen Modification :
CD34
Clone Name :
REA1164
Isotype :
REA Control Antibody (S), human IgG1
Size :
30 tests in 60 µL
US List Price :
136 USD
Product Description :
Identification and enumeration of CD34+ cells by flow cytometry
ALTnames :
gp105-120, Mucosialin, My10
Specificity :
human
Concentration :
1:50
Uses :
For research use only
Application Summary :
Flow cytometry, MICS (MACSima Imaging Cyclic Staining), Immunofluorescence, Immunohistochemistry
Storage :
Store protected from light at 2–8 °C. Do not freeze.
company information
Miltenyi Biotec
Friedrich-Ebert-Strae 68
51429 Bergisch Gladbach
51429 Bergisch Gladbach
macs@miltenyibiotec.com
https://www.miltenyibiotec.com1 800 FOR MACS
headquarters: Germany
questions and comments